Results for delamaniidiga translation from Estonian to English

delamaniidiga ravitud patsientidel on täheldatud qt-intervalli pikenemist.
qt prolongation has been observed in patients treated with delamanid.

moksifloksatsiini manustamist koos delamaniidiga multiresistentse tuberkuloosiga patsientidele ei ole uuritud.
co-administration of moxifloxacin and delamanid in mdr-tb patients has not been studied.

puuduvad andmed ravi kohta delamaniidiga enam kui 24 järjestikuse nädala jooksul.
there are no data on treatment with delamanid for more than 24 consecutive weeks.

selliste patsientide ekg-d tuleb kogu delamaniidiga ravimise jooksul väga sageli jälgida.
such patients should receive very frequent monitoring of ecg throughout the full delamanid treatment period.

enne ravi alustamist delamaniidiga ja kogu ravikuuri ajal üks kord kuus on soovitatav teha elektrokardiogramme (ekg).
it is recommended that electrocardiograms (ecg) should be obtained before initiation of treatment and monthly during the full course of treatment with delamanid.

multiresistentse tuberkuloosi kliinilises uuringus seostati delamaniidiga ravitud patsientidel hüpoalbumineemiat suurenenud qtc-intervalli pikenemise riskiga.
in a clinical study, the presence of hypoalbuminaemia was associated with an increased risk of prolongation of the qtc interval in delamanid treated patients.

kasutamine samaaegselt delamaniidiga suurendas oluliselt, ligikaudu 25% võrra etambutooli püsikontsentratsioone vereplasmas, kuid selle kliiniline olulisus ei ole teada.
co-administration with delamanid significantly increased steady state plasma concentrations of ethambutol by approximately 25%, the clinical relevance is unknown.

kui qtc-intervalli kestus ületab mees-/naispatsiendil 450/470 ms ravi ajal delamaniidiga, tuleb neid patsiente sagedamini ekg-ga jälgida.
if the qtc interval duration exceeds 450/470 ms for male/female patients during delamanid treatment, these patients should be administered more frequent ecg monitoring.

delamaniidiga ravitud patsientide kõige sagedamini täheldatud kõrvaltoimed (st esinemissagedus > 10%) on iiveldus (38,3%), oksendamine (33%) ja pearinglus (30,2).
the most frequently observed adverse drug reactions in patients treated with delamanid (i.e. incidence > 10%) are nausea (38.3%), vomiting (33%), and dizziness (30.2%).